Cerecor and Aevi Genomic Medicine Complete Merger

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced Monday it has completed the previously announced acquisition of Aevi Genomic Medicine (NASDAQ: GNMX) in an all-stock transaction valued at approximately $15.6 million at close, plus contingent value rights (CVRs) for up to an additional $6.5 million in subsequent payments based on clinical and/or regulatory milestones. Cerecor’s pipeline now includes six clinical-stage assets, accelerating the Company’s transformation into a research and development organization focused on developing new medicines for unmet needs in rare diseases, particularly for pediatric patients.

Read the full article: Cerecor and Aevi Genomic Medicine Complete Merger //

Source: https://www.globenewswire.com/news-release/2020/02/03/1979058/0/en/Cerecor-and-Aevi-Genomic-Medicine-Complete-Merger.html

Scroll to Top